NewsBenzingaBiofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses Benzinga 2026.10.08 13:24 (GMT+0) Open on Benzinga Other news EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts Stocks Settle Higher as Chipmakers and AI-Infrastructure Stocks Rebound JP Morgan Maintains Overweight on First Solar, Lowers Price Target to $252 Karooooo Q2 Adj. EPS $0.57, Inline, Sales $100.292M Beat $97.720M Estimate Karooooo Affirms FY2027 GAAP EPS Guidance of $2.35-$2.44 vs $2.41 Est Lear Appoints Jared Fedele CFO, Effective March 1, 2027, Succeeding Jason Cardew
